Head and Neck Squamous Cell Carcinoma (HNSCC) Clinical Trials

Find Head and Neck Squamous Cell Carcinoma (HNSCC) Clinical Trials Near You

A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1 (CPS ≥20) (HexAgon-HN)

Status: Active_not_recruiting
Location: See all (87) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY

This seamless phase 2/3 randomized controlled study will evaluate the efficacy and safety of the hexavalent OX40 agonist antibody INBRX-106 combined with the anti-PD-1 antibody pembrolizumab versus pembrolizumab (+ placebo in phase 3) as first-line treatment for patients with locally advanced recurrent or metastatic head and neck squamous cell carcinoma (R/M HSNSCC) incurable by local therapies, expressing PD-L1 with a combined proportion score (CPS) ≥20.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Has histologically or cytologically confirmed diagnosis of metastatic, recurrent head and neck squamous cell carcinoma (HNSCC) that is considered incurable by local therapies.

• Has tumor PD-L1 expression of CPS ≥20. Tumor tissue must be provided for PD-L1 biomarker analysis.

• Has human papilloma virus (HPV) testing results for oropharyngeal cancer by p16 immunohistochemistry (IHC) testing.

• Has measurable disease per RECIST 1.1 guidelines.

• Has the primary tumor location of the oral cavity, oropharynx, hypopharynx, or larynx.

• Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

• Female patients of childbearing potential must have a negative highly sensitive pregnancy test within 72 hours prior to randomization and must not be breastfeeding.

• Male and female patients of childbearing potential must be willing to completely abstain from heterosexual sex or agree to use a highly effective method of contraception.

Locations
United States
California
City of Hope Medical Center
Duarte
Los Angeles Cancer Network (LACN)
Los Angeles
UC Davis
Sacramento
Medical Oncology Associates of San Diego
San Diego
Sarcoma Oncology Center
Santa Monica
Delaware
ChristianaCare Health Services
Newark
Florida
University of Florida UF Health Cancer Center
Gainesville
The Oncology Institute of Hope & Innovation
Miami
Mid Florida Hematology and Oncology Center
Orange City
Cleveland Clinic Florida, The Maroone Cancer Center
Weston
Illinois
University of Illinois Cancer Center
Chicago
Kentucky
Norton Cancer Institute
Louisville
Massachusetts
Massachusetts General Hospital
Boston
Michigan
Karmanos Cancer Institute
Detroit
Missouri
Washington University St. Louis
St Louis
Montana
Intermountain Health, St. Vincent Regional Hospital, Cancer Centers of Montana
Billings
North Carolina
UNC Lineberger Comprehensive Cancer Center
Chapel Hill
Nebraska
Oncology Hematology West, PC dba Nebraska Cancer Specialists
Omaha
New Mexico
Christus St. Vincent Regional Cancer Center
Santa Fe
Nevada
Comprehensive Cancer Centers of Nevada
Las Vegas
Oklahoma
Oklahoma University Stephenson Cancer Center
Oklahoma City
Oregon
Oregon Health & Science University
Portland
Pennsylvania
UPMC Hillman Cancer Center
Pittsburgh
Texas
CHRISTUS Spohn Cancer Center
Corpus Christi
Virginia
VCU Massey Comprehensive Cancer Center
Richmond
Other Locations
Australia
Royal Adelaide Hospital
Adelaide
Belgium
Antwerp University Hospital
Edegem
University Hospital Brussels
Jette
Chu Ucl Namur Site De Sainte-Elisabeth
Namur
Vitaz
Sint-niklaas
Bulgaria
Multiprofile Hospital for Active Treatment - Uni Hospital Ltd, Medical Oncology Dept
Panagyurishte
Complex Oncological Center Plovdiv EOOD Dept of Med Oncology and Oncological Diseases in Hematology
Plovdiv
Multiprofile Hospital for Active Treatment Sveta Sofia, Department of Medical Oncology
Sofia
Uni Multiprofile Hospital for Active Treatment Tsaritsa Yoanna - ISUL EAD Clinic of Medical Oncology
Sofia
France
CH Annecy Genevois
Annecy
Centre Jean Perrin
Clermont-ferrand
Cenre Oscar Lambret
Lille
Centre Leon Berard
Lyon
UNEOS-Hopital R.SCHUMAN
Metz
Italy
European Institute of Oncology
Milan
Istituto Nazionale Tumori IRCCS - (National Cancer Institute)
Milan
Istituto Nazionale Tumori IRCCS - Fondazione Giovanni Pascale (National Cancer Institute)
Naples
Fondazione IRCCS Policlinico San Matteo
Pavia
Malaysia
Hospital Canselor Tuanku Muhriz (HCTM) UKM
Cheras
Hospital Universiti Sains Malaysia
Kubang Kerian
Sarawak General Hospital
Kuching
Beacon Hospital
Petaling Jaya
Thomson Hospital Kota Damansara
Petaling Jaya
Institut Kanser Negara
Putrajaya
Poland
Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy Oddział w Gliwicach
Gliwice
Przychodnia Lekarska KOMED
Konin
Provita Profamilia
Piotrkow Trybunalski
Republic of Korea
Keimyung University Dongsan Hospital of Korea
Daegu
Gachon University Gil Medical Center of Korea
Seoul
Korea Cancer Center Hospital
Seoul
Korea University Anam Hospital
Seoul
Korea University Guro Hospital
Seoul
Severance Hospital, Yonsei University Health System
Seoul
The Catholic University of Korea, Eunpyeong St. Mary's Hospital
Seoul
Pusan National University Yangsan Hospital
Yangsan
Romania
ARENSIA Clinic Oncology Institute Bucharest
Bucharest
Arensia Exploratory Medicine S.R.L in collaboration with Prof. Dr. Ion Chiricuta Oncology Institute
Cluj-napoca, Cluj
Sc Centrul de Oncologie Sf Nectarie Srl
Craiova
Sc Oncolab Srl
Craiova
Spain
Complexo Hospitalario Universitario A Coruña
A Coruña
Hospital Clinic de Barcelona
Barcelona
Intituto Catalán de Oncología
Barcelona
IOB / Institute of Oncology, Hospital Quirónsalud Barcelona
Barcelona
Hospital Universitario Gregorio Marañón
Madrid
MD Anderson Cancer Centre
Madrid
Hospital Universitario de Navarra
Pamplona
Hospital Clinico Universitario de Santiago de Compostela
Santiago
Hospital Universitario y Politécnico La Fe
Valencia
Taiwan
Changhua Christian Medical Foundation Changhua Christian Hospital
Changhua
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City
Taichung Veterans General Hospital
Taichung
National Cheng Kung University Hospital
Tainan
National Taiwan University Hospital
Taipei
Taipei Veterans General Hospital
Taipei
United Kingdom
NHS Grampian / Aberdeen Royal Infirmary
Aberdeen
Addenbrooke's Hospital
Cambridge
The Royal Marsden NHS Foundation Trust, Chelsea
Chelsea
The Christie NHS Foundation Trust
Manchester
The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Northern Centre for Cancer Care, Freeman Hospital
Newcastle Upon Tyne
Mount Vernon Cancer Centre
Northwood
Norwich and Norfolk University Hospital
Norwich
The Royal Marsden NHS Foundation Trust, Sutton
Sutton
Time Frame
Start Date: 2024-05-14
Completion Date: 2029-05
Participants
Target number of participants: 410
Treatments
Experimental: INBRX-106 plus pembrolizumab
Participants will receive INBRX-106 plus pembrolizumab, both given by intravenous (IV) infusion every 3 weeks (QW3)
Active_comparator: pembrolizumab monotherapy (+ placebo in phase 3 part)
Participants will receive pembrolizumab (plus placebo in Phase 3), given by intravenous (IV) infusion every 3 weeks (QW3)
Related Therapeutic Areas
Head and Neck Squamous Cell Carcinoma (HNSCC)
Sponsors
Leads: Inhibrx Biosciences, Inc

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

An Open-label Phase II/III Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1

An Open-label Phase II/III Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1

Who is this study for: Patients with unresectable recurrent, or metastatic head and neck squamous cell carcinoma which is positive for human papilloma virus 16 and expresses PD-L1
Enrollment Status: Recruiting
Publish Date: April 15, 2026
Intervention Type: Biological
Study Drugs: BNT113, Pembrolizumab
Study Phase: Phase 2/Phase 3

A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma

A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma

Enrollment Status: Recruiting
Publish Date: March 27, 2026
Intervention Type: Drug
Study Phase: Phase 3

A Randomized, Controlled, Multicenter Phase 3 Study of AK112 in Combination With AK117 Versus Pembrolizumab as First Line Treatment for a Programmed Cell Death-ligand 1 (PD-L1) Positive Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

A Randomized, Controlled, Multicenter Phase 3 Study of AK112 in Combination With AK117 Versus Pembrolizumab as First Line Treatment for a Programmed Cell Death-ligand 1 (PD-L1) Positive Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Enrollment Status: Recruiting
Publish Date: November 14, 2024
Intervention Type: Drug
Study Phase: Phase 3
View All